Biomarkers Identified for Irritable Bowel Syndrome
|
By LabMedica International staff writers Posted on 02 May 2018 |

Image: The nanoLC-Ultra 1D+ for nanoflow liquid chromatography (Photo courtesy of Eksigent).
The causes of gastrointestinal complaints in irritable bowel syndrome (IBS) remain poorly understood. Altered nerve function has emerged as an important pathogenic factor as IBS mucosal biopsy supernatants consistently activate enteric and sensory neurons.
The enteric nervous system (ENS) in the gut wall coordinates and maintains normal gut functions. Its central role for normal motility, secretion and immune cell function also indicates that altered ENS function is often associated with gut pathologies. Irritable bowel syndrome (IBS) is a functional gastrointestinal disease and belongs with a population prevalence of ~11% to the most common gut disorders.
An international team of scientists led by those at the Technical University of Munich (Freising, Germany) studied the effect of supernatants from seven healthy controls (HC), 20 IBS and 12 ulcerative colitis (UC) patients on human and guinea pig submucous neurons were studied with neuroimaging techniques. They identified differentially expressed proteins with proteome analysis. Macroscopically normal intestinal specimens (as determined by visual inspection by a pathologist) were taken from 105 patients (51 male, 54 female, mean age 69 years) who underwent surgery for various pathologies.
Analysis of imaging studies was performed with Neuroplex 10.1.2. Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed by coupling an Eksigent nanoLC-Ultra 1D+ to an Orbitrap Elite mass spectrometer.
The team found that for the nerve activating properties of IBS and UC supernatants were mainly due to proteases, which are not only enzymes but also important signaling molecules. However, there was an important difference. While the nerve activation from IBS supernatants was mediated by proteases signaling via the protease activated receptor type 1, this receptor played no role in the effect of UC supernatants. They found an IBS-specific protein pattern, in particular an IBS-specific protease profile. Proteome analysis revealed 204 differently expressed proteins in IBS supernatants and four proteases that were only enhanced in IBS supernatants.
The team addressed the translational relevance of the finding by asking the question how they could influence the nerve activation, besides using PAR1 blockers. They reported that using a protease inhibitor from a probiotic Bifidobacterium longum strain, this inhibitor blocked the nerve activation triggered by the IBS supernatant. The study was published on March 12, 2018, in the journal Public Library of Science ONE.
Related Links:
Technical University of Munich
The enteric nervous system (ENS) in the gut wall coordinates and maintains normal gut functions. Its central role for normal motility, secretion and immune cell function also indicates that altered ENS function is often associated with gut pathologies. Irritable bowel syndrome (IBS) is a functional gastrointestinal disease and belongs with a population prevalence of ~11% to the most common gut disorders.
An international team of scientists led by those at the Technical University of Munich (Freising, Germany) studied the effect of supernatants from seven healthy controls (HC), 20 IBS and 12 ulcerative colitis (UC) patients on human and guinea pig submucous neurons were studied with neuroimaging techniques. They identified differentially expressed proteins with proteome analysis. Macroscopically normal intestinal specimens (as determined by visual inspection by a pathologist) were taken from 105 patients (51 male, 54 female, mean age 69 years) who underwent surgery for various pathologies.
Analysis of imaging studies was performed with Neuroplex 10.1.2. Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed by coupling an Eksigent nanoLC-Ultra 1D+ to an Orbitrap Elite mass spectrometer.
The team found that for the nerve activating properties of IBS and UC supernatants were mainly due to proteases, which are not only enzymes but also important signaling molecules. However, there was an important difference. While the nerve activation from IBS supernatants was mediated by proteases signaling via the protease activated receptor type 1, this receptor played no role in the effect of UC supernatants. They found an IBS-specific protein pattern, in particular an IBS-specific protease profile. Proteome analysis revealed 204 differently expressed proteins in IBS supernatants and four proteases that were only enhanced in IBS supernatants.
The team addressed the translational relevance of the finding by asking the question how they could influence the nerve activation, besides using PAR1 blockers. They reported that using a protease inhibitor from a probiotic Bifidobacterium longum strain, this inhibitor blocked the nerve activation triggered by the IBS supernatant. The study was published on March 12, 2018, in the journal Public Library of Science ONE.
Related Links:
Technical University of Munich
Latest Pathology News
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreGenomic Assay Predicts Recurrence Risk in Noninvasive Breast Cancer
Ductal carcinoma in situ (DCIS) is a common noninvasive breast malignancy in which treatment decisions hinge on accurately estimating recurrence risk. Approximately 60,000 women are diagnosed each year... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more
New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. Recurrent febrile episodes complicate recognition... Read more
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more








